Melanotan II vs Nonapeptide-1
How Melanotan II and Nonapeptide-1 compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Melanotan II and Nonapeptide-1 come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Melanotan II vs Nonapeptide-1, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Melanotan II | Nonapeptide-1 |
|---|---|---|
| What it is | Synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH); a non-selective melanocortin-receptor agonist | Synthetic nine-amino-acid alpha-MSH antagonist peptide used as a topical cosmetic ingredient |
| Class / category | Melanocortin | Cosmetic / skin |
| Evidence tier | Human (controlled) · Helped | In-vitro · Unclear · none in humans |
| Studied / approved for | Skin tanning / photoprotection; Sexual arousal / erectile function; Vitiligo repigmentation | Skin brightening in topical cosmetics; Melasma maintenance as one ingredient in combination products |
| US regulatory status (2026) | research use only (as of Jul 2026) | unscheduled (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 1 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Unknown |
| Key risks | Melanotan II's tanning effect is real, but so are its downsides. Nausea and facial flushing are common early on, and the effect that matters most is on the skin itself: Melanotan II can darken existing moles and prompt new ones, which makes tracking any change in a mole harder at exactly the wrong time. Case reports link Melanotan II use to melanoma and to changes in atypical moles. Long-term human safety data do not exist, and the vials sold online are unregulated research chemicals of variable purity and sterility. | Nonapeptide-1 has no published long-term human safety trial as a standalone ingredient. Small randomized studies of multi-ingredient topical products reported adverse events at the finished-product level, which cannot identify the peptide as the cause or rule it out. Irritation or allergy remains possible with any topical formula, and safety depends on the whole product. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Melanotan II vs Nonapeptide-1: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Melanotan II
Melanotan II's evidence sits at human (controlled), a more human tier than Nonapeptide-1's in-vitro. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Melanotan II (CID 92432) — compound record, PubChem (National Library of Medicine)
- 2.Melanotan II — human-tagged research (PubMed, National Library of Medicine)
- 3.Melanotan II (MT-II) as an adjunct to NB-UVB phototherapy for vitiligo (NCT07437560) — ClinicalTrials.gov
- 4.FDA — Drugs (approval status & unapproved-drug information)
- 5.Global Drug Reference Online (GlobalDRO) — prohibited-substance status in sport
- 6.Nonapeptide-1 — PubChem compound record (CID 10418849)